{"id":24706,"date":"2025-03-21T06:50:00","date_gmt":"2025-03-21T06:50:00","guid":{"rendered":"https:\/\/www.businessmole.com\/?p=24706"},"modified":"2025-03-20T18:05:54","modified_gmt":"2025-03-20T18:05:54","slug":"trilateral-research-works-to-remove-ai-bias-in-skin-cancer-detection","status":"publish","type":"post","link":"https:\/\/www.businessmole.com\/trilateral-research-works-to-remove-ai-bias-in-skin-cancer-detection\/","title":{"rendered":"Trilateral Research Works to Remove AI Bias in Skin Cancer Detection"},"content":{"rendered":"\n<p><a href=\"https:\/\/trilateralresearch.com\/\">Trilateral Research<\/a> is developing a cutting-edge <strong>AI-powered screening tool<\/strong> aimed at <strong>enhancing early melanoma detection<\/strong>.<\/p>\n\n\n\n<p>In collaboration with <strong>healthcare providers, AI developers, and research institutions<\/strong>, Trilateral is contributing to the <strong>iToBoS Project (Intelligent Total Body Scanner for Early Detection of Melanoma)<\/strong>. This system integrates <strong>AI and advanced imaging technology<\/strong> to provide a <strong>more detailed and comprehensive approach<\/strong> to skin health analysis.<\/p>\n\n\n\n<p>A significant challenge in <strong>AI-driven skin cancer detection<\/strong> is <strong>bias<\/strong>, as many existing models rely on <strong>narrow datasets<\/strong> that do not adequately represent <strong>diverse skin types<\/strong>. This can result in <strong>inaccurate diagnoses and disparities in patient outcomes<\/strong>, particularly for <strong>underrepresented groups<\/strong>.<\/p>\n\n\n\n<p>To address this, Trilateral is dedicated to <strong>minimising bias within the iToBoS tool<\/strong>, making it more <strong>transparent, inclusive, and effective<\/strong> across all skin types. The team is actively working with partners to refine AI technology in skin cancer detection, ensuring that diagnoses are <strong>consistent and equitable<\/strong> for all patients.<\/p>\n\n\n\n<p>As part of the <strong>iToBoS project<\/strong>, Trilateral has conducted a comprehensive <strong>evaluation of the AI system<\/strong>, ensuring it operates fairly, transparently, and inclusively by utilising a <strong>diverse and representative dataset<\/strong>.<\/p>\n\n\n\n<p>A vital element of this initiative is the <strong>Risk Assessment Model<\/strong>, developed by the <strong><a href=\"https:\/\/www.ntua.gr\/en\/\">National Technical University of Athens (NTUA)<\/a><\/strong>, which assesses the <strong>reliability of AI-based diagnoses<\/strong> and highlights areas for improvement. Trilateral\u2019s experts have provided <strong>strategic recommendations<\/strong> to enhance <strong>inclusivity, strengthen decision-making<\/strong>, and ensure the AI tool delivers <strong>accurate and fair results for all patients<\/strong>.<\/p>\n\n\n\n<p>Trilateral and its partners are continuously <strong>improving how the AI system processes and learns from patient data<\/strong>, expanding its ability to <strong>accurately detect melanoma across all skin types<\/strong>. By incorporating <strong>best practices in fairness and transparency<\/strong>, the system is being designed to be <strong>both adaptable and dependable for clinical use<\/strong>. The <strong>iToBoS project<\/strong> aligns with Trilateral\u2019s overarching mission to ensure that <strong>AI technology is developed responsibly and meets ethical and regulatory requirements<\/strong>.<\/p>\n\n\n\n<p>By setting <strong>new standards for fairness and ethical deployment<\/strong>, the <strong>iToBoS project<\/strong> is shaping the <strong>future of AI in healthcare<\/strong>. Trilateral Research remains committed to advancing <strong>AI-driven solutions that prioritise patient safety, accuracy, and fairness<\/strong>, ensuring <strong>technological progress benefits all communities equally<\/strong>.<\/p>\n\n\n\n<p>To learn more about <strong>Trilateral Research<\/strong>, its <strong>products, services, or research innovations<\/strong>, visit: <strong><a href=\"https:\/\/trilateralresearch.com\/contact-us\">https:\/\/trilateralresearch.com\/contact-us<\/a><\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"Trilateral Research is developing a cutting-edge AI-powered screening tool aimed at enhancing early melanoma detection. In collaboration with&hellip;\n","protected":false},"author":10,"featured_media":24707,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","csco_singular_sidebar":"","csco_page_header_type":"","csco_appearance_masonry":"","csco_page_load_nextpost":"","csco_post_video_location":[],"csco_post_video_location_hash":"","csco_post_video_url":"","csco_post_video_bg_start_time":0,"csco_post_video_bg_end_time":0},"categories":[696,712,718],"tags":[],"_links":{"self":[{"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/posts\/24706"}],"collection":[{"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/comments?post=24706"}],"version-history":[{"count":1,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/posts\/24706\/revisions"}],"predecessor-version":[{"id":24708,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/posts\/24706\/revisions\/24708"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/media\/24707"}],"wp:attachment":[{"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/media?parent=24706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/categories?post=24706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/tags?post=24706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}